Professor Ahmed Ahmed, director of the ovarian cancer cell laboratory at MRC Weatherall Institute of Molecular Medicine at the University of Oxford, is leading the research into the first ovarian cancer vaccine.
The hope is that the jab could one day be given to women preventatively with the aim of eliminating the disease.
Here is what we know so far about the groundbreaking research
– What is ovarian cancer?
Ovarian cancer affects the ovaries – two small oval-shaped organs that are part of the female reproductive system.
Cancer can occur in the ovaries when abnormal cells begin to grow and divide in an uncontrolled way which eventually form a tumour.
If not caught early, the cancerous cells can grow into the surrounding tissues and may spread to other parts of the body.
There are around 7,500 new ovarian cancer cases in the UK every year.
Just over a third of women (35%) with ovarian cancer will survive for 10 years after diagnosis.
Around 4,100 women die from the disease each year in the UK.
– What are the standard treatments?
Treatment for ovarian cancer depends on a number of factors, including the size and type of ovarian cancer, where it is and whether it has spread.
The main treatments are surgery and chemotherapy, other treatments include targeted medicines and hormone treatments.
– Tell me about the new vaccine
Scientists at the University of Oxford are creating OvarianVax.
It is hoped the jab will work by teaching the immune system to recognise and attack the earliest stages of ovarian cancer.
Experts envisage that this cancer vaccine will work in a preventative way by stopping the very first few cancer cells that develop.
– When will it be ready?
It will still take many years for the vaccine to reach a point where it is widely available.
At the moment, scientists are identifying cellular targets for the vaccine.
They will establish which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system, and how effectively the vaccine kills mini-models of ovarian cancer in the lab.
If this research is successful, work will then begin on clinical trials of the vaccine.
Once the various stages of human clinical trials have been completed, health officials can then consider whether it is safe and effective for widespread use.
Experts from Cancer Research UK, which is funding the study, have described the work as an “exciting step forwards”.
Professor Ahmed Ahmed, director of the ovarian cancer cell laboratory at MRC Weatherall Institute of Molecular Medicine the University of Oxford, said the aim of the jab is to eliminate ovarian cancer.
Join BusinessDay whatsapp Channel, to stay up to date
Open In Whatsapp
